You are here:

lisdexamfetamine dimesylate (Elvanse Adult)

Advice

following a full submission

lisdexamfetamine dimesylate (Elvanse Adult®) is accepted for use within NHS Scotland.

Indication under review: as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults. Based on clinical judgment, patients should have ADHD of at least moderate severity.

Three phase III and two phase IV clinical studies in adults with ADHD demonstrated that lisdexamfetamine improves the symptoms of ADHD compared with placebo.
 

Drug Details

Drug Name: lisdexamfetamine dimesylate (Elvanse Adult)
SMC Drug ID: 1079/15
Manufacturer: Shire Pharmaceuticals
Indication: Indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults.
BNF Category:
Sub Category: 4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder
Submission Type: Full submission
Status: Accepted
Date Advice Published: 7 September 2015

Back